君实生物-U
(688180)
| 流通市值：233.19亿 | | | 总市值：300.64亿 |
| 流通股本：7.65亿 | | | 总股本：9.86亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,271,200,009.95 | 786,056,275.43 | 380,804,271.07 | 1,502,549,915.75 |
| 营业收入 | 1,271,200,009.95 | 786,056,275.43 | 380,804,271.07 | 1,502,549,915.75 |
| 二、营业总成本 | 2,261,152,311.32 | 1,434,750,281.6 | 703,379,531.6 | 3,811,859,509.4 |
| 营业成本 | 325,339,075.87 | 210,419,748.58 | 108,094,203.03 | 540,976,390.72 |
| 税金及附加 | 17,132,866.24 | 11,611,663.96 | 5,643,377.09 | 19,704,320.97 |
| 销售费用 | 683,629,829.87 | 427,553,592.62 | 191,592,867.84 | 844,355,927 |
| 管理费用 | 353,242,444.41 | 239,719,730.6 | 123,309,563.52 | 536,439,566.54 |
| 研发费用 | 874,268,925.53 | 546,376,150.47 | 276,292,124.92 | 1,937,469,544.84 |
| 财务费用 | 7,539,169.4 | -930,604.63 | -1,552,604.8 | -67,086,240.67 |
| 其中:利息费用 | 32,912,225.93 | 20,686,103.23 | 11,684,234.17 | 23,006,975.29 |
| 其中:利息收入 | 32,647,344.93 | 24,453,746.85 | 13,959,616.53 | 99,426,230.82 |
| 加:公允价值变动收益 | -30,053,190.85 | -32,147,749.55 | -1,154,733.64 | -149,177,392.25 |
| 加:投资收益 | -17,147,524.18 | -27,835,848.07 | -7,397,349.03 | 73,990,355.55 |
| 资产处置收益 | 12,891,972.67 | 12,938,477.3 | 23,722,664.29 | 29,406,432.28 |
| 资产减值损失(新) | -3,641,769.04 | -381,606.68 | 6,318,900.98 | -126,313,501.28 |
| 信用减值损失(新) | 11,174,765.63 | 10,415,866.31 | 2,695,299.66 | -23,483,189.23 |
| 其他收益 | 47,607,041.87 | 10,019,476.8 | 5,554,844.4 | 47,444,534.82 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -969,121,005.27 | -675,685,390.06 | -292,835,633.87 | -2,457,442,353.76 |
| 加:营业外收入 | 877,766.7 | 818,405.29 | 17,162.5 | 3,913,286.2 |
| 减:营业外支出 | 16,400,811.52 | 9,290,891.21 | 3,730,898.82 | 38,165,533.03 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -984,644,050.09 | -684,157,875.98 | -296,549,370.19 | -2,491,694,600.59 |
| 减:所得税费用 | 4,081,640.85 | 3,551,165.51 | 3,098,595.27 | 43,994,697.26 |
| 六、净利润 | -988,725,690.94 | -687,709,041.49 | -299,647,965.46 | -2,535,689,297.85 |
| 持续经营净利润 | -988,725,690.94 | -687,709,041.49 | -299,647,965.46 | -2,535,689,297.85 |
| 归属于母公司股东的净利润 | -926,768,557.18 | -644,954,683.24 | -283,029,082.76 | -2,283,431,860.25 |
| 少数股东损益 | -61,957,133.76 | -42,754,358.25 | -16,618,882.7 | -252,257,437.6 |
| (一)基本每股收益 | -0.94 | -0.65 | -0.29 | -2.32 |
| (二)稀释每股收益 | -0.94 | -0.65 | -0.29 | -2.32 |
| 八、其他综合收益 | -47,944,698.9 | -24,342,498.84 | 852,568.88 | -73,658,461.53 |
| 归属于母公司股东的其他综合收益 | -47,944,698.9 | -24,342,498.84 | 852,568.88 | -73,658,461.53 |
| 九、综合收益总额 | -1,036,670,389.84 | -712,051,540.33 | -298,795,396.58 | -2,609,347,759.38 |
| 归属于母公司股东的综合收益总额 | -974,713,256.08 | -669,297,182.08 | -282,176,513.88 | -2,357,090,321.78 |
| 归属于少数股东的综合收益总额 | -61,957,133.76 | -42,754,358.25 | -16,618,882.7 | -252,257,437.6 |
| 公告日期 | 2024-10-30 | 2024-08-31 | 2024-04-30 | 2024-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |